

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Attorney Docket No.: 2813-L

Stewart D. Lyman and M. Patricia Beckmann

Art Unit:

1644

Serial No.:

08/994,468

Examiner:

P. Gambel

Filed:

December 19, 1997

CPA Filed:

May 26, 2000

CPA Filed:

March 4, 2003

For:

MEDIUM CONTAINING FLT3 LIGAND FOR CULTURING

HEMATOPOIETIC CELLS (as amended)

## Continuation Prosecution Application Amendment and Reply

RECEIVED

**BOX CPA** 

Commissioner for Patents Washington, D.C. 20231

JUL 2 3 2003

TECH CENTER 1600/2900

Dear Sir:

In response to the Advisory Action, having a mailing date of October 10, 2002, Applicants respectfully submit this Continuation Prosecution Application and accompanying Amendment and Reply. A Notice of Appeal was filed on September 4, 2002. A Petition for a 4-month extension of time and requisite fee are included. In view of the following amendments and accompanying remarks, Applicants respectfully request reconsideration and allowance of the pending claims.

Kindly amend the subject application as described below. *In the Specification:* 

The "Cross-Reference To Related Applications" at page 1, has been amended to read as follows:

This application is a continuation of United States Application 08/444,627, filed May 19, 1995, now abandoned, which is a divisional of United States Application 08/243,545 filed May 11, 1994, now allowed and issued as U.S. Patent No. 5,554,512, which is a continuation-in-part of United States Application 08/209,502 filed March 7, 1994, now abandoned.

In the Claims:

Please cancel claims 1-8.